pharma · Metastatic Pancreatic Adenocarcinoma · Primary Biliary Cholangitis
Ipsen
Ipsen clinical programs — 10 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 70, Rue Balard, Paris, Île-de-France 75015, FR
- Employees
- 6,584
- Programs
- 27
- Drugs
- 36
- Patents
- 0
Ipsen projects
10 ClinicalTrials.gov programs sponsored by Ipsen.
Ipsen has 10 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
A4250-015
Ipsen
Alagille Syndrome
1 trial -
Botulinum toxin type A
Ipsen
Low Back Pain
1 trial -
CLIN-10200-458
Ipsen
Treatment of moderate to severe glabellar lines
1 trial -
CLIN-52120-463
Ipsen
Chronic migraine
1 trial -
CLIN-52120-464
Ipsen
Episodic Migraine
1 trial -
D-US-60010-001
Ipsen
Metastatic Pancreatic Adenocarcinoma
1 trial -
Odevixibat
Ipsen
Biliary Atresia
1 trial -
elafibranor, Elafibranor Placebo
Ipsen
Primary Biliary Cholangitis (PBC)
1 trial -
elafibranor, Placebo
Ipsen
Primary Biliary Cholangitis
1 trial -
elafibranor, Placebo tablet
Ipsen
Primary Biliary Cholangitis
1 trial
Frequently asked questions
How many clinical projects does Ipsen have?
10 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.